USFDA makes 22 observations post inspection of Lupin's Mandideep facilities

Lupin said the observations are "largely procedural in nature with some gaps identified in the aseptic processing areas of the Cephalosporin API block” and the company is confident of addressing them satisfactorily.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2QCXT7F
via IFTTT